Mazdutide
aka IBI362
Mechanism
Mazdutide is a dual GLP-1 / glucagon receptor agonist licensed from Eli Lilly to Innovent Biologics for Greater China. Approved by China's NMPA in June 2025 for chronic weight management and in September 2025 for glycemic control in type 2 diabetes; NOT FDA-approved in the US.
Identification
| CAS number | 2259884-03-0 |
|---|---|
| Molecular formula | C207H317N45O65 |
| Typical dose | 2–10 mg subcutaneous once weekly (escalating regimen; approved maintenance doses in China 4.5–9 mg/week) |
| Half-life | ~5–7 days (clinical PK: t1/2 range 174.8–1075.7 h across doses) |
Vendors selling Mazdutide
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Skye Peptides | 6 mg | $99.00 | — | 90 |
| Peptidology | 10 mg | $79.99 | — | 89 |
| Cocer Peptides | 10 mg | $260.00 | — | 82 |
| Certified Peptides | 10 mg | $128.00 | — | 62 |
| Peptiatlas | — | — | — | 51 |
| zztai Peptide Ltd | — | — | — | 43 |
| AMC Essentials | 6 mg | $89.99 | — | — |
| Flawless Compounds | — | — | — | — |
| Genetic Peptide | 5 mg | $100.00 | — | — |
| Genetic Peptide | 10 mg | $100.00 | — | — |
| Genetic Peptide | 15 mg | $100.00 | — | — |
| Genetic Peptide | 30 mg | $100.00 | — | — |
| Genetic Peptide | 60 mg | $100.00 | — | — |
| Kimera Chems | — | $111.99 | — | — |
| Polaris Peptides | 6 mg | $100.00 | — | — |
| Solution Peptides | 6 mg | $80.00 | — | — |
| Southern Aminos | 10 mg | $74.25 | — | — |
| Welli Labs | — | $79.99 | — | — |
Research
Aim To assess the effects of mazdutide on body weight, HbA1c, metabolic outcomes, and adverse events in adults with overweight/obesity and/or type 2 diabetes (T2D).
source →Importance Obesity is a worldwide problem and a major public health issue in China. Objective To evaluate the efficacy and safety of mazdutide (a once-weekly glucagon and glucagon-like peptide-1 receptor dual agonist) in Chinese adults with obesity (defined as a body mass index of ≥30).
source →Adolescent obesity is an escalating global health concern associated with increased risks of cardiovascular disease, type 2 diabetes mellitus, and long-term metabolic complications.
source →Introduction Mazdutide is a dual glucagon-like peptide-1 receptor (GLP-1 R) and glucagon receptor (GCGR) agonist representing a new generation of incretin-based therapeutics for obesity and type 2 diabetes.
source →Background: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most prevalent chronic liver disorder globally. Mazdutide has shown clinical benefits in weight management and metabolic regulation, indicating its potential as a therapeutic agent for MASLD.
source →Background Once-weekly dual glucagon and glucagon-like peptide-1 receptor agonist mazdutide, administered at 4 and 6 mg, provides substantial weight loss in Chinese adults with overweight or obesity. This trial aimed to evaluate the efficacy and safety of mazdutide 9 mg in Chinese adults with obesity.
source →Introduction Glucagon receptor agonists (GRAs) are an emerging class of therapies for obesity and type 2 diabetes, demonstrating encouraging metabolic and weight-reducing effects.
source →Background Mazdutide, a dual GLP-1 and glucagon receptor agonist, shows promise for weight loss and glycaemic control. This study evaluates its efficacy in non-diabetic patients with obesity.
source →Objective To conduct a systematic, multi-dimensional clinical evaluation of five long-acting glucagon-like peptide-1 receptor agonists (GLP-1RAs) available in China, providing evidence-based guidance for clinical preference and institutional formulary selection.
source →Despite advances in type 2 diabetes (T2D) management, unmet needs remain for therapies that effectively control hyperglycaemia while addressing comorbid metabolic disorders 1,2 .
source →Obesity is a chronic, progressive, and relapsing disease. Although lifestyle interventions and anti-obesity medications are effective for inducing weight loss, evidence regarding their role in long-term weight maintenance after pharmacologically induced weight reduction remains limited.
source →A multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in participants with mild to moderate hypertension complicated by overweight/obesity who have not received antihypertensive drug treatment
source →This multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the effect of mazdutide, a dual GLP-1/GCG receptor agonist, on coronary plaque progression assessed by coronary computed tomography angiography (CCTA) in patients with coronary atherosclerosis and overweight or obesity.
source →Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with monotherapy. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration remain significant concerns.
source →This trial is conducted in China.
source →The main purpose of this study is to learn about the safety and tolerability of LY3305677 when given to participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
source →This trial is aimed to investigate the safety, tolerability, PK and PD of multiple subcutaneous injections of IBI362 in Chinese patients with type 2 diabetes who have poor glycemic control after lifestyle or metformin intervention
source →The purposes of this study are to determine: * The safety of LY3305677 and any side effects that might be associated with it. * How much LY3305677 gets into the bloodstream and how long it takes the body to remove it in healthy participants, including those of Japanese origin.
source →